Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
50 studies found for:    eye diseases AND university of iowa | Exclude Unknown
Show Display Options
Rank Status Study
21 Active, not recruiting Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)
Condition: Age Related Macular Degeneration
Intervention: Drug: 3 dose cohorts gene therapy
22 Recruiting Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors
Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Choroid Plexus Tumor;   Childhood Craniopharyngioma;   Childhood Grade I Meningioma;   Childhood Grade II Meningioma;   Childhood Grade III Meningioma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Infratentorial Ependymoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Oligodendroglioma;   Childhood Supratentorial Ependymoma;   Newly Diagnosed Childhood Ependymoma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma
Intervention: Other: cytology specimen collection procedure
23 Active, not recruiting Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers
Conditions: Extraocular Retinoblastoma;   Intraocular Retinoblastoma;   Recurrent Retinoblastoma
Interventions: Other: questionnaire administration;   Other: laboratory biomarker analysis
24 Completed Idiopathic Intracranial Hypertension Treatment Trial
Condition: Idiopathic Intracranial Hypertension
Interventions: Drug: Acetazolamide;   Drug: Placebo;   Behavioral: Formal weight loss counselling program
25 Completed A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: Fabrazyme (agalsidase beta)
26 Recruiting Inflammation Inhibition in Prediabetic Humans
Conditions: Prediabetes;   Obese
Interventions: Drug: Salsalate;   Drug: Placebo
27 Completed
Has Results
Sudden Deafness Treatment Trial
Condition: Sudden Deafness
Interventions: Drug: prednisone;   Drug: methylprednisolone sodium succinate
28 Completed Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)
Condition: Restless Legs Syndrome
Intervention: Drug: Pramipexole
29 Completed The Effects of Diquafosol Tetrasodium Ophthalmic Solution, 2% in Subjects With Dry Eye Disease
Condition: Dry Eye Disease
Interventions: Drug: Diquafosol tetrasodium ophthalmic solution, 2%;   Drug: Placebo
30 Recruiting Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia/Transient Myeloproliferative Disorder;   Acute Undifferentiated Leukemia;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Essential Thrombocythemia;   Extramedullary Plasmacytoma;   Intraocular Lymphoma;   Isolated Plasmacytoma of Bone;   Juvenile Myelomonocytic Leukemia;   Long-term Effects Secondary to Cancer Therapy in Children;   Mast Cell Leukemia;   Meningeal Chronic Myelogenous Leukemia;   Monoclonal Gammopathy of Undetermined Significance;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Primary Central Nervous System Hodgkin Lymphoma;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Primary Myelofibrosis;   Primary Systemic Amyloidosis;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   T-cell Large Granular Lymphocyte Leukemia;   Unspecified Childhood Solid Tumor, Protocol Specific;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
Interventions: Other: survey administration;   Procedure: assessment of therapy complications;   Procedure: long-term screening;   Procedure: study of high risk factors
31 Active, not recruiting Efficacy of Methotrexate in Myasthenia Gravis
Condition: Myasthenia Gravis
Interventions: Drug: Methotrexate;   Other: Placebo
32 Active, not recruiting Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Condition: Leukemia
Interventions: Drug: cytarabine;   Drug: daunorubicin;   Drug: midostaurin;   Other: placebo;   Drug: dexamethasone acetate
33 Completed Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma
Conditions: Brain and Central Nervous System Tumors;   Lymphoma;   Neuroblastoma;   Retinoblastoma;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Drug: becatecarin
34 Completed S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma
Condition: Malignant Neoplasms of Eye, Brain and Other Parts of Central Nervous System
Interventions: Drug: carmustine;   Radiation: radiation therapy;   Drug: O6-Benzylguanine
35 Active, not recruiting Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for DME
Condition: Diabetic Macular Edema
Interventions: Drug: 2.0  mg intravitreal aflibercept;   Drug: 1.25 mg intravitreal bevacizumab;   Drug: 0.3 mg intravitreal ranibizumab
36 Completed The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period
Condition: Blepharitis
Interventions: Drug: Azithromycin ophthalmic solution, 1%;   Drug: Placebo
37 Completed
Has Results
Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)
Conditions: Vitreous Hemorrhage;   Proliferative Diabetic Retinopathy
Interventions: Drug: Ranibizumab;   Drug: Saline
38 Completed Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia
Condition: Leukemia
Interventions: Drug: cytarabine;   Drug: dexamethasone;   Drug: etoposide;   Drug: idarubicin;   Drug: ifosfamide;   Drug: leucovorin calcium;   Drug: mesna;   Drug: pegaspargase;   Drug: therapeutic hydrocortisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: low-LET cobalt-60 gamma ray therapy;   Radiation: low-LET electron therapy;   Radiation: low-LET photon therapy;   Drug: Methotrexate
39 Recruiting Treatment for CI-DME in Eyes With Very Good VA Study
Condition: Diabetic Macular Edema
Interventions: Procedure: Prompt Laser;   Drug: Prompt aflibercept;   Procedure: Deferred laser;   Drug: Deferred aflibercept
40 Suspended Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
Conditions: Neurofibromatosis Type 1;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Visual Pathway Glioma
Interventions: Drug: Lenalidomide;   Other: Pharmacological Study

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-50) Show next page of results    Last Page
Indicates status has not been verified in more than two years